



MARSHALL UNIVERSITY
Joan C. Edwards School of Medicine

Translational Research and personalized medicine

February 28, 2013

**Nader G Abraham, PhD, Dr.h.c.,
FAHA**

**Vice Dean for Research,
JCESOM**


WE ARE... MARSHALL.

1600 Medical Center Drive • Suite 3400 • Huntington, West Virginia 25755-3655 • Tel 304/691-1700 • Fax 304/691-1726

A State University of West Virginia • An Affirmative Action/Equal Opportunity Employer

Increasing Prevalence of obesity and Diabetes


Worldwide Growth of Diabetes



- The rapidly rising prevalence of type 2 diabetes is due to:
 - Aging population
 - Unhealthy diets
 - Sedentary lifestyles
 - Obesity prevalence
- Limitations of current therapies

- 47MM diabetics in 7 major markets (18MM in US)
- 51% of diabetics are not diagnosed or treated
- **600,000 obese-diabetics in WV**

Disruption Of Redox Homeostasis in Obesity and diabetes : A Vicious Pathological Loop




Dysfunctional Adipogenesis


Targeted Induction Of HO-1 In Adipocytes: Effects On Diet-induced Obesity

- HO-1 gene targeting to adipocytes utilizing lentiviral vector for gene delivery to fat stem cells.
- Examining the effects on visceral adiposity and associated vascular dysfunction in mice fed a high fat diet

Viral vector construction and adipocyte-specific expression of the transgene *in vivo*



Experimental protocols




Effect of HO-1 Gene targeting to fat tissues on mice fed HF diets, mice appearance

Lean
vehicle

Vehicle

Lenti-aP2-HO-1

Lenti-aP2-GFP



Clinical Implications

This study provides strong evidence that long-term using lentivirus (FDA approved) targeting HO-1 to fat stem cells provide a therapeutic approach to address the risk factor of obesity

Stem cells Therapy

- **Application of stem cells for human with myocardial infraction**

Criteria for patient participation

- Patients scheduled for coronary artery bypass grafting.
- Acute transmural myocardial infarct is extensive with isotopic, LVEF \leq 30%.
- Patients are \leq 70 years.



Methods and Procedures

- ✓ Infarct size is stable (3-5 days post infarct)
- ✓ Harvest 200 ml of blood after 6-7 days
- ✓ CD34+ selection using immunoselection and expansion
- ✓ Re-inject stem cells into the infarct tissue.
This process takes about 25-30 days.

Patient



Apheresis

200 ml



**PBSC
Collection**

**CD34⁺ Stem Cell
Immunoisolation**



**Selective
Expansion**




**Purified CD34⁺
cells**



**% 30 loss, Subset
Evaluation**

**CD 133+ KDR+
Cardiomyocyte**


Inject 7X10⁷



Bypass Surgery

Heart Function Survey

**Ejection Fraction Cardiac
Muscle Contractility (PetScan)
(PetScan) peptide**



12 months myocardial function improvement Petscan

Patient	LVEF before /12 months	LVEDD (mm) before/12 months
1	34% / 38%	
2	30% / 44 %	
3	33% / 53%	
4	31% / 47%	
5	36% / 51%	
6	40% / 56%	
7	30% / 54%	

Segment area			Area kinesis (- to ++ +)	NYHA grade before/6 months
				IV/III
				IV/I
				IV/I
				IV/III
				IV/II
				IV/I
				IV/I

Regeneration Therapy / Cell Therapy

Stem cells are promising therapeutic tools with wide applications including Metabolic syndrome, Cardiovascular disease , renal repair and Neurodegenerative diseases